Feed NBRVF
NB

Nabriva Therapeutics plc

NBRVF · OTC

$0.00 +0.00% (+$0.00)
Market Cap $323.0
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9
Valuation
100 /100
Cheap
P/S 0.00x
P/B 0.00x
P/E N/A
Growth
78 /100
Growing
Rev. growth 66.35%
Book val. growth 56.95%
EPS growth N/A
Profitability
6 /100
Weak
Gross margin 19.87%
FCF margin 103.52%
Net margin 160.33%
Quality
20 /100
Poor
ROIC 634.43%
Asset turnover 1.12x
ROA 180.03%
Debt
51 /100
Moderate
Debt/Equity 1.59x
Net debt/EBITDA 0.13x
Current ratio 1.13x
Stability
35 /100
Moderate
Beta -0.68x
Profitable years 0
Rev. volatility 258.14%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NBRVF
Online

Sector

Healthcare

Industry

Biotechnology

CEO

H. Michael Hogan

Employees

39

Headquarters

Dublin

Upcoming events

13 NOV

Earnings

Upcoming earnings report

53d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.